FASTER, PLEASE: Superbug antibiotics: New drugs advance amid R&D investment shortfall. “Today, there are only two Big Pharma companies, GlaxoSmithKline and AstraZeneca, with active antibiotic R&D programs . . . . In 1990, there were nearly 20.”
InstaPundit is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.